financetom
Business
financetom
/
Business
/
Digital freight platform Full Truck Alliance Q2 revenue, net income rises
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Digital freight platform Full Truck Alliance Q2 revenue, net income rises
Aug 21, 2025 3:54 AM

Overview

* Full Truck Alliance Q2 2025 revenue rises 17.2% yr/yr, driven by transaction services

* Net income for Q2 2025 increases 50.5% yr/yr, reflecting operational efficiency

* Co announces semi-annual cash dividend for second half of 2025

Outlook

* Company expects Q3 2025 revenue between RMB3.07 bln and RMB3.17 bln

* Company anticipates significant decline in freight brokerage revenue

* Excluding freight brokerage, Q3 revenue growth expected at 23.4% to 29.1%

* Service fee rate increase may impact shippers' costs

Result Drivers

* TRANSACTION SERVICES - Revenue from transaction services increased 39.4% yr/yr, driven by higher order volume and transaction fees

* COST REDUCTION - Cost of revenues decreased 5.6%, aided by lower tax costs net of government grants

* USER GROWTH - Fulfilled orders rose 23.8% and average shipper MAUs increased 19.3%, boosting revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 RMB 3.24

Revenue bln

Q2 RMB 1.35

Adjusted bln

Net

Income

Q2 Net RMB 1.26

Income bln

Q2 RMB 1.23

Adjusted bln

Operatin

g Income

Q2 RMB 1.14

Operatin bln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Full Truck Alliance Co Ltd ( YMM ) is $14.60, about 24.6% above its August 20 closing price of $11.01

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
Nov 12, 2025
$142.6 million cash and cash equivalents and marketable securities as of September 30, 2025  Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to optimize study design in alignment with IMG-007’s unique molecular attributes; strong patient enrollment continues Novel alopecia areata data including biomarkers from Phase 1b/2a study to be presented at upcoming Inflammatory...
Ovid Therapeutics Q3 revenue slightly beats expectations
Ovid Therapeutics Q3 revenue slightly beats expectations
Nov 12, 2025
Overview * Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations * Meg Alexander appointed CEO, effective January 2026 Outlook * Ovid plans Phase 2a trial for OV329 in Q2 2026 * Company expects OV350 data in Q4 2025 * Ovid anticipates OV4071 clinical trial start in Q2 2026 Result Drivers * Research and development expenses were $5.9...
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Loblaw Companies Q3 Adjusted Earnings, Revenue, Beat Estimates
Nov 12, 2025
07:14 AM EST, 11/12/2025 (MT Newswires) -- Loblaw Companies ( LBLCF ) said Wednesday that third-quarter adjusted earnings and revenue both rose, with both measures beating estimates. Adjusted earnings increased 8% to $828 million or $0.69 per diluted share, from $767 million, or $0.62 per diluted share in the prior year period. The result was a cent above the consensus...
TScan Therapeutics Q3 revenue jumps
TScan Therapeutics Q3 revenue jumps
Nov 12, 2025
Overview * TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements * Net loss for Q3 2025 increased due to higher R&D expenses * Company reached FDA agreement on pivotal trial design for TSC-101 Outlook * Company expects cash reserves to fund operations into the second half of 2027 * Enrollment in solid tumor trial paused to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved